Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) is now available.
Jacobio Pharmaceuticals has received a US$100 million upfront payment from AstraZeneca under their license and collaboration agreement for the pan-KRAS inhibitor JAB-23E73. The inflow significantly strengthens Jacobio’s cash reserves and is expected to accelerate development across its oncology pipeline, underlining the strategic value of its KRAS-focused assets and reinforcing its position as an emerging innovator in targeted cancer therapies.
The agreement with AstraZeneca highlights growing big-pharma interest in next-generation KRAS inhibitors, a hotly contested area in oncology drug development. For investors and stakeholders, the sizeable non-dilutive funding reduces near-term financing pressure, supports continued R&D in multiple pathways, and may enhance Jacobio’s competitiveness and partnering profile in the global oncology market.
The most recent analyst rating on (HK:1167) stock is a Buy with a HK$10.34 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage biopharmaceutical company focused on targeted oncology and tumor immunotherapy, with pipelines in KRAS, STING, P53 and MYC pathways. The company operates R&D centers in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery and immunostimulatory antibody-drug conjugate platforms to develop innovative cancer therapies aimed at global leadership in drug R&D.
Average Trading Volume: 3,662,776
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.63B
Find detailed analytics on 1167 stock on TipRanks’ Stock Analysis page.